Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00468312 |
This study is designed to assess the effectiveness of MFNS once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total symptom score.
Condition | Intervention | Phase |
---|---|---|
Seasonal Allergic Rhinitis |
Drug: Mometasone furoate nasal spray |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 Mcg QD in the Treatment of Seasonal Allergic Rhinitis |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | P05106 |
Study First Received: | April 30, 2007 |
Last Updated: | September 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00468312 |
Health Authority: | United States: Food and Drug Administration |
Hypersensitivity Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases Mometasone furoate |
Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate Rhinitis Respiratory Hypersensitivity |
Anti-Inflammatory Agents Immune System Diseases Therapeutic Uses |
Anti-Allergic Agents Pharmacologic Actions Nose Diseases |